期刊文献+

利培酮和其主要活性代谢产物9-羟基利培酮代谢动力学模型的建立和鉴别 被引量:5

Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone
下载PDF
导出
摘要 建立利培酮(RIP)和其活性代谢物9-羟基利培酮代谢动力学模型,并考察其在健康男性志愿者中的药动学特征。22名健康男性志愿者单剂量口服利培酮2 mg,在服药前及服药后96 h内的不同时间点取血。HPLC-MS法测定RIP和9-羟基利培酮的血药浓度;依据RIP和9-羟基利培酮的T1/2确定志愿者中CYP2D6快代谢(EM)、中代谢(IM)和慢代谢(PM)型的分布,相似转换法(similarity transformation)进行模型结构鉴别,依据鉴别结果进行模型修正;加权最小二乘法进行模型参数估算;以Monte Carlo法产生的模拟数据进行模型验证,评估模型参数求算的准确性。22名健康男性志愿者中EM型18名,IM型4名;模型鉴别结果提示假设模型不可整体鉴别,当获知RIP代谢为9-羟基利培酮的转换分数时,模型参数均可求算;模型对于EM型和IM型RIP和9-羟基利培酮血药浓度经时过程和主要药动学参数AUC0-t,Cmax和Tmax预测效果均较好。RIP代谢为9-羟基利培酮的转换速率常数EM型为(0.12±0.08)h-1,IM型为(0.014±0.007)h-1,RIP的消除速率常数EM型为(0.25±0.18)h-1,IM型为(0.05±0.23)h-1。模型验证结果提示:参数估算值的均值与实际值较为接近;大多数参数的平均预测误差均在±15%内。模型具有代表性,不同CYP2D6表型者RIP代谢药动学参数差异较大,可为RIP进一步临床研究打下基础。同时模型结构鉴别可为复杂药动学模型的参数求算和实验设计提供有力的帮助。 To develop a parent-metabolite pharmacokinetic model for risperidone (RIP) and its major active metabolite (9-hydroxyrisperidone) and investigate their pharmacokinetics characteristics in healthy male volunteers, twenty-two healthy volunteers were orally given a single dose of 2 mg RIP. Plasma samples were collected in the period of 96 hours and concentrations of RIP and 9-hydroxyrisperidone were measured by a validated HPLC/MS method. CYP2D6 phenotypes were identified by the T1/2 of RIP and 9-hydroxyrisperidone according to the literature. Model structure identifiability analysis was performed by the similarity transformation approach to investigate whether the unknown parameters of the proposed model could be estimated from the designed experiment. Pharmacokinetics parameters were estimated using weighted least squares method, and the final pharmacokinetics model were tested and evaluated by Monte Carlo simulation. Eighteen volunteers were phenotyped as extensive metabolizers (EM) and four volunteers were identified as intermediate metabolizers (IM) The final model included central and peripheral compartment for both parent (RIP) and metabolite (9-hydroxyrisperidone) respectively. Model structure identifiability analysis indicated that the proposed model was local identifiable. However, if the ratio of RIP converted to 9-hydroxyrisperidone was assumed to be 32% in EM, and 22% in IM, the model could be globally identifiable. The predicted time-concentration curve and AUC0-1, Cmax, Tmax of RIP and 9-hydroxyrisperidone estimated by the established model were in agreement with the observations and noncompartment analysis. Rate constant of RIP conversion to 9-hydroxyrisperidone was (0. 12 ±0. 08) h^-1 and (0. 014 ±0. 007) h ^-1 for EM and IM, respectively. Elimination rate constants of RIP were (0. 25± 0. 18) and (0.05 ±0.23) h^-1 for EM and IM, respectively. Model validation result showed that all parameters derived from the concentration data fitted well with the theoretical value, with mean prediction error of most PK parameter within + 15%. The established model well defined the disposition of RIP and 9-hydroxyrisperidone simultaneously and showed large inter-individual pharmacokinetics variation in different CYP2D6 phenotype. The model also provide a useful approach to characterize pharmacokinetics of other parent-metabolite drugs.
出处 《药学学报》 CAS CSCD 北大核心 2007年第6期631-638,共8页 Acta Pharmaceutica Sinica
关键词 利培酮 9-羟基利培酮 代谢动力学 CYP2D6代谢表型 模型结构鉴别 相似转换法 MONTE CARLO模拟 risperidone 9-hydroxyrisperidone parent-metabolite pharmacokinetic CYP2D6 phenotype model structural identifiability similarity transformation Monte Carlo simulation
  • 相关文献

参考文献26

  • 1He H,Richardson JS.A pharmacological,pharmacokinetic and clinical overview of risperidone,a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors[J].Int Clin Psychopharmacol,1995,10:19-30.
  • 2Yasui-Furukori N,Hidestrand M,Spina E,et al.Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes[J].Drug Metab Dispos,2001,29:1263-1268.
  • 3Hsieh KP,Lin YY,Cheng CL,et al.Novel mutations of CYP3A4 in Chinese[J].Drug Metab Dispos,2001,29:268-273.
  • 4成碟,徐为人,刘昌孝.细胞色素P450(CYP450)遗传多态性研究进展[J].中国药理学通报,2006,22(12):1409-1414. 被引量:44
  • 5Berecz R,LLerena A,de la Rubia A,et al.Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients[J].Pharmacopsychiatry,2002,35:231-234.
  • 6魏传梅,王本杰,郭瑞臣.以利培酮为探针的健康中国人羟基化表型测定[J].山东大学学报(医学版),2005,43(12):1178-1181. 被引量:1
  • 7Mannens G,Huang ML,Meuldermans W,et al.Absorption,metabolism,and excretion of ripseridone in humans[J].Drug Metab Dispos,1993,21:1134-1141.
  • 8段小涛,陈笑艳,张逸凡,钟大放.液相色谱-串联质谱法测定人血浆中的利培酮[J].药学学报,2006,41(7):684-688. 被引量:10
  • 9柳晓泉,曹于平,谭力,于丽芬.维拉帕米及其主要代谢物在健康人体内的药物动力学[J].中国药科大学学报,1996,27(10):601-604. 被引量:2
  • 10Zhang L,Jiao Z,Yao Z,et al.The validation of an LC-MS method for the determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma[J].Chromatographia,2005,61:245-251.

二级参考文献73

  • 1陈騉,王睿.药物代谢酶细胞色素P4502C9研究进展[J].中国临床药理学与治疗学,2004,9(6):601-606. 被引量:15
  • 2周燕文,李新春,杨玉芳,李健.盐酸吡格列酮胶囊的人体相对生物利用度[J].中国医院药学杂志,2004,24(10):598-600. 被引量:5
  • 3丁俊杰,焦正,李中东,施孝金,钟明康.Bootstrap法验证有限抽样法多元回归模型[J].中国卫生统计,2004,21(5):289-292. 被引量:1
  • 4焦正,蒋新国,钟明康,陆伟跃.药物临床研究的计算机模拟[J].中国新药与临床杂志,2005,24(6):491-496. 被引量:13
  • 5谭力,杨胜茹,柳晓泉,袁倚盛.高效液相色谱法同时测定盐酸维拉帕米及其主要代谢产物[J].药学学报,1995,30(9):689-693. 被引量:8
  • 6Bullingham RE, Nicholls A J, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil [ J ]. Clin Pharmacokinet, 1998,34:429 -455.
  • 7Shum B, Duffull SB, Taylor PJ, et al. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil [ J ]. Br J Clin Pharmacol, 2003, 56 : 188 - 197.
  • 8Le Guellec C, Bourgoin H,Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients [ J ]. Clin Pharmacokinet, 2004,43 :253 - 266.
  • 9Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? [ J ]. Ther Drug Monit, 2003,25 : 137 - 157.
  • 10Shen J, Jiao Z, Yu YQ, et al. Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 817:207 -213.

共引文献74

同被引文献72

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部